Drug Profile
ASP 5633
Alternative Names: ASP-5633Latest Information Update: 21 Oct 2015
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stress incontinence
Most Recent Events
- 21 Oct 2015 Phase-I development for Stress incontinence is ongoing in Japan
- 01 Oct 2015 Discontinued - Phase-I for Stress incontinence in Japan (PO)
- 01 Aug 2014 Phase-I clinical trials in Stress incontinence in Japan (PO)